IL318955A - תרכובות פירידינון מותמר כמעכבי cbl-b - Google Patents

תרכובות פירידינון מותמר כמעכבי cbl-b

Info

Publication number
IL318955A
IL318955A IL318955A IL31895525A IL318955A IL 318955 A IL318955 A IL 318955A IL 318955 A IL318955 A IL 318955A IL 31895525 A IL31895525 A IL 31895525A IL 318955 A IL318955 A IL 318955A
Authority
IL
Israel
Prior art keywords
cbl
inhibitors
pyridinone compounds
substituted pyridinone
substituted
Prior art date
Application number
IL318955A
Other languages
English (en)
Original Assignee
Glenmark Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Ltd filed Critical Glenmark Pharmaceuticals Ltd
Publication of IL318955A publication Critical patent/IL318955A/he

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL318955A 2022-08-16 2023-08-15 תרכובות פירידינון מותמר כמעכבי cbl-b IL318955A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202221046493 2022-08-16
PCT/IB2023/058197 WO2024038378A1 (en) 2022-08-16 2023-08-15 Substituted pyridinone compounds as cbl-b inhibitors

Publications (1)

Publication Number Publication Date
IL318955A true IL318955A (he) 2025-04-01

Family

ID=87929171

Family Applications (1)

Application Number Title Priority Date Filing Date
IL318955A IL318955A (he) 2022-08-16 2023-08-15 תרכובות פירידינון מותמר כמעכבי cbl-b

Country Status (13)

Country Link
EP (1) EP4573085A1 (he)
JP (1) JP2025525947A (he)
KR (1) KR20250050018A (he)
CN (1) CN119546587A (he)
AU (1) AU2023326220A1 (he)
CA (1) CA3258870A1 (he)
CL (1) CL2025000120A1 (he)
CO (1) CO2025003090A2 (he)
CU (1) CU20250003A7 (he)
IL (1) IL318955A (he)
MX (1) MX2025001865A (he)
PE (1) PE20251389A1 (he)
WO (1) WO2024038378A1 (he)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025076299A1 (en) * 2023-10-06 2025-04-10 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2025214476A1 (zh) * 2024-04-11 2025-10-16 北京诺诚健华医药科技有限公司 Cbl-b抑制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019148005A1 (en) 2018-01-26 2019-08-01 Nurix Therapeutics, Inc. Inhibitors of cbl-b and methods of use thereof
EP3953346A1 (en) 2019-04-09 2022-02-16 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
EP3969447A1 (en) 2019-05-17 2022-03-23 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof
MX2021015675A (es) 2019-06-26 2022-02-03 Nurix Therapeutics Inc Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos.
WO2021021761A1 (en) 2019-07-30 2021-02-04 Nurix Therapeutics, Inc. Urea, amide, and substituted heteroaryl compounds for cbl-b inhibition
EP4034141A1 (en) 2019-09-24 2022-08-03 Nurix Therapeutics, Inc. Cbl inhibitors and compositions for expansion of immune cells
WO2022169998A1 (en) * 2021-02-03 2022-08-11 Genentech, Inc. Amides as cbl-b inhibitors

Also Published As

Publication number Publication date
CA3258870A1 (en) 2024-02-22
CO2025003090A2 (es) 2025-03-27
KR20250050018A (ko) 2025-04-14
MX2025001865A (es) 2025-04-02
JP2025525947A (ja) 2025-08-07
CU20250003A7 (es) 2025-09-01
AU2023326220A1 (en) 2025-02-20
PE20251389A1 (es) 2025-05-22
CL2025000120A1 (es) 2025-06-13
WO2024038378A1 (en) 2024-02-22
CN119546587A (zh) 2025-02-28
EP4573085A1 (en) 2025-06-25

Similar Documents

Publication Publication Date Title
IL310403A (he) תולדות פירידין מותמרות כמעכבי sarm1
IL325340A (he) מעכבי kras
IL308421A (he) תרכובות הטרוציקליות מוחלפות
IL307448A (he) נגזרות זרחן כמעכבים חדשים ל- sos1
IL318955A (he) תרכובות פירידינון מותמר כמעכבי cbl-b
SG11202013016YA (en) Heterocyclic compounds as trk inhibitors
IL299664A (he) תרכובות הטרוציקליות
EP4146649A4 (en) COMPOUNDS AS BCL-2 INHIBITORS
IL308422A (he) תרכובות הטרוציקליות מוחלפות
IL314049A (he) מעכבי parp7
IL281742B2 (he) תרכובות חדשות כמעכבים של nadph אוקסידאז
IL311354A (he) פולימורפים כמעכבי erbb
IL320185A (he) תרכובת הטרוציקלית
GB202200735D0 (en) Compounds
IL320747A (he) נגזרות פיפרידין כמעקבי 3mettl
ES3062046T3 (en) Heterocyclic carboxylate compounds as glycolate oxidase inhibitors
GB202300881D0 (en) Inhibitor compounds
EP4029853A4 (en) SYNTHETIC METHOD APPLIED TO A HETEROCYCLIC INTERMEDIATE OF KRAS INHIBITOR DRUGS
EP4457224A4 (en) HETEROCYCLICAL COMPOUNDS
EP4304588A4 (en) COMPOUNDS CONTAINING TETRAHYDROINDOLIZIN-1-CARBOXAMIDE AS BCL-2 INHIBITORS
IL288472A (he) תרכובות טטרציקליות כמעכבי cdc7
IL299175A (he) תולדות טטראזול כמעכבי trpa1
EP3976038A4 (en) HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS
EP3947369A4 (en) HETEROCYCLIC COMPOUNDS AS BCR-ABL INHIBITORS
EP4433478A4 (en) COMPOUNDS USED AS BCL-2 INHIBITORS